CYP2C19 variation and citalopram response. - Wikidata - awgldk - TriplyDB

CYP2C19 variation and citalopram response.

CYP2C19 variation and citalopram response.

http://www.wikidata.org/entity/Q34954026

about

Applications of CYP450 testing in the clinical setting The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene.Towards the clinical implementation of pharmacogenetics in bipolar disorder.Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.Exploring the role of drug-metabolising enzymes in antidepressant side effects.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.PharmGKB summary: citalopram pharmacokinetics pathway.Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Pharmacogenetics of chronic pain and its treatment.Abandoning personalization to get to precision in the pharmacotherapy of depression.Mechanisms of antidepressant resistance Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.Maternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy.Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study.Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies.Digging up the human genome: current progress in deciphering adverse drug reactions.Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.Pharmacogenomics in psychiatry - Clinical innovation utilised by the Therapeutic Goods Administration and Food and Drug Administration.Seeking an objective diagnosis of depression.A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort.A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.

P2860

Q24621760-E8749852-BFEF-4381-9E36-82B0390A3176 Q26741187-45612ED8-7FEA-4CDA-A182-4E570500C7BC Q26996411-C4C9321C-FB79-4D1A-8692-EF7BD3395600 Q33652540-CF72A1A9-5D4B-45C8-B049-36DBBFA12BE9 Q33688133-1FF11876-6EFC-47FA-93F1-CC46E49CBFA2 Q34273354-683DBCFB-6035-4FA6-AB16-6DAC1CAD00B8 Q34306561-EC56175D-48F1-4F87-AF1F-926125518416 Q34307589-8FECB4B0-E8CC-41A5-A010-303E3B33F9A5 Q34706677-411EAB98-1A2B-4BE3-B9C6-8684C7D2EF5A Q34879739-09F702D5-8CC0-4381-8F8D-2E1DBB4561F3 Q35537682-BB27090C-077F-47B2-A5A3-5C2214591A8C Q35780023-81C8B75C-AC9B-41DE-BCC3-8F9D50375EDA Q35952367-283618D7-F11A-440D-8846-3C7B1314EEB5 Q35952370-1E8B4723-00B5-44B7-97E8-946B40D8D0B2 Q36113601-0953344B-D619-4701-BA0A-8CC2518510BE Q36887128-13045A36-19B5-48E1-998B-C12818538BCD Q36900075-271FF863-DB5C-41D3-BC2E-995D799E6724 Q37274682-A72FE378-4055-4415-BD45-3CC0DC253F1D Q37334088-738B061A-503B-4EBF-B276-6A66E2EEBA5B Q37711609-EB163EE4-5635-4C3E-95D8-931203869AE0 Q37742091-9761E492-B0EF-4FDC-A25F-DC05F66CFAF8 Q38154911-6769610A-0B6A-45C3-BB1D-125F40CBF216 Q38154915-57A423A8-4B8D-4628-BE33-13D5E84527DD Q38239777-622BE972-1321-4248-AD1C-86695C90D326 Q38357402-607B0EA0-9E06-446C-8CC3-11F8DFA73C39 Q38453405-1B845033-8141-49C3-A63E-1CBFA5EEB93C Q38484370-7B5A0D4F-82C5-4896-972E-46C3C027B07C Q38509732-6369ADD8-DC5A-46B4-B8E4-A01DF4A85582 Q38731079-F677DB6F-5BED-422A-962D-F5FEFE92550D Q38983579-16313DAF-2E3C-4A11-ADD7-D20312E33F14 Q39441964-4A61A297-62C2-4762-96C7-B4B6016404D7 Q40569531-7E9CBEE1-2D37-4047-8270-935343598922 Q41005811-9E69E343-EADF-4C2A-A21F-816DD7186320 Q41288507-FBF43339-3545-4FFA-A0B5-0A3319D735EB Q41889353-D889F7B3-F865-4F8C-85EE-4B40C8272D36 Q45729383-592EB3D4-68E5-45E3-B0AB-F158D4633BAB Q48041467-0F224608-558D-4664-B0A1-0CAE4318AD13 Q48048867-AFAF84AD-CB85-49E7-AC09-1DFACF118BC9 Q48170776-05212E1C-612C-4A4F-B35A-7B067E35A509 Q48235443-C041CDB2-B9E6-4807-BABB-345196F780E3

P2860

CYP2C19 variation and citalopram response.

http://www.wikidata.org/entity/Q34954026

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

CYP2C19 variation and citalopram response.

@ast

CYP2C19 variation and citalopram response.

@en

CYP2C19 variation and citalopram response.

@nl

type

label

CYP2C19 variation and citalopram response.

@ast

CYP2C19 variation and citalopram response.

@en

CYP2C19 variation and citalopram response.

@nl

prefLabel

CYP2C19 variation and citalopram response.

@ast

CYP2C19 variation and citalopram response.

@en

CYP2C19 variation and citalopram response.

@nl

P1433

Q34954026-08238A63-A198-4CA5-A23E-F930A0077D62

P1476

Q34954026-9719116C-065D-415B-87EE-8BA4178FCB7E

P2093

Q34954026-0428A5DB-CCBF-4D1A-9EDB-401A8133FCD8

Q34954026-2AC45C7F-5235-4E41-B439-A4A83A5096C0

Q34954026-397C0C76-688F-4828-B4C7-BA61E4ECF332

Q34954026-39ACA047-BB81-4EF6-8E68-EB1697D8AE75

Q34954026-63635EBD-6AA4-40D8-9599-6AA9DE615D49

Q34954026-927092B6-4254-431C-9104-D2DF7049B0F1

Q34954026-A1F9E2CB-9289-4065-A04C-8039FB9B5921

P2860

Q34954026-120721DF-94DA-4F43-B9CA-67F74D1D605F

Q34954026-2923F85E-A2EA-43B7-9EA1-812EC78E38E6

Q34954026-2D972DAD-A4F4-403C-AB7B-BFA0E1C4CBDD

Q34954026-41395C8F-3C1D-4339-B532-6E0D7099351E

Q34954026-520D4701-9EE1-4379-8C92-D0C6CD0A95C0

Q34954026-57DA5FCA-70F3-4DE0-939E-523E21A04B8F

Q34954026-73A70915-6D46-4860-B405-825F1FA9EC5E

Q34954026-74C633B8-F98B-46E3-AC54-FEBEC2033903

Q34954026-7F1A638F-296D-4EEF-8124-EA5E0F6D19C4

Q34954026-837FDE35-4C2C-4A6C-A748-D795E19B0C35

P304

Q34954026-1C6E9710-9246-49C3-AEBD-B437EE58AF74

P31

Q34954026-5561F979-F1CA-4FAB-9034-9AD0885358EC

P356

Q34954026-2BEFD177-299E-4996-9F1C-5FD99CA8AEDF

P433

Q34954026-6DFE8022-140E-472E-90D7-416EB7AAA9F3

P478

Q34954026-073400C2-1DDB-4BFC-8880-0723B659C6BC

P50

Q34954026-37DA4537-33EE-422B-B6F8-332B1753E9C3

Q34954026-7CDB688D-7BAA-4D60-B1A3-700ED651A28D

Q34954026-C4D45C1B-02D4-45E0-9D5E-D02E12E81D7F

P577

Q34954026-9159DE7A-BE79-4B80-9296-9780580F879D

P5875

Q34954026-BEE28800-8351-4D23-9D85-31206086BF41

P698

Q34954026-73FD0438-C0CC-4193-ABF2-2884866931F7

P932

Q34954026-A12D7D54-A99F-4EA9-BF7B-8B0140D76AA2

P356

FPC.0B013E328340BC5A

P1433

Pharmacogenetics and Genomics

P1476

CYP2C19 variation and citalopram response.

@en

P2093

David A Mrazek

http://www.w3.org/2001/XMLSchema#string

Dennis J O'Kane

http://www.w3.org/2001/XMLSchema#string

Joanna M Biernacka

http://www.w3.org/2001/XMLSchema#string

John L Black

http://www.w3.org/2001/XMLSchema#string

Karen A Snyder

http://www.w3.org/2001/XMLSchema#string

Maureen S Drews

http://www.w3.org/2001/XMLSchema#string

Susanna R Stevens

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

A genomewide association study of citalopram response in major depressive disorder

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.

CYP2D6: novel genomic structures and alleles.

An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E328340BC5A

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Augustus John Rush

Richard Weinshilboum

Julie M. Cunningham

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49715575

http://www.w3.org/2001/XMLSchema#string

P698

21192344

http://www.w3.org/2001/XMLSchema#string

P932

3090085

http://www.w3.org/2001/XMLSchema#string